HAVE ANY QUESTIONS? CLICK HERE
Biomatlante: a new step towards the MDR
- Biomatlante News
Just after BSI last January, TÜV Süd Product Service GmbH is now the second Notified Body designated to issue CE Marking certifications under the European Medical Devices Regulation (MDR).
Biomatlante receives MDSAP Accreditation
- Biomatlante News
Biomatlante, a world leader in synthetic bone regeneration technologies, is pleased to announce the obtention of the MDSAP* accreditation on the new ISO 13485:2016 Certificate.
BIOMATLANTE announces the appointment of its new CEO
- Biomatlante News
Julien Dert named as new CEO of Biomatlante, Chantal Gobin continues as Chairman of the Board
Biomatlante, a world leader in synthetic bone regeneration technologies, is pleased to announce the appointment of its new CEO, Julien Dert, being effective on February 1st, 2019.
Clinical Performance of hydrogel- bioceramic Putty for Bone Regeneration in maxillofacial surgery
- Biomatlante News
The article shows the valorization of results of a non interventional clinical study of 78 patients with the product In’Oss™ in association with a collagen resorbable membrane in maxillofacial surgery. The safety and efficacy of In’Oss has been demonstrated, as well as the performance of EZ Cure membrane associated to it.
Variation of bone forming ability with the physicochemical properties of calcium phosphate bone substitutes
- Biomatlante News
Six commercially available CaP bone substitutes (Bio-Oss, Actifuse, Bi-Ostetic, MBCP, Vitoss and chronOs) as well as two tricalcium phosphate (TCP) ceramics with either a micron-scale (TCP-B) or submicronscale (TCP-S) surface structure are characterized and their bone forming potential is evaluated in a canine ectopic implantation model.
MBCP+™, the adapted matrix for tissue engineering
- Biomatlante News
After the success of the European program REBORNE (FP7) focused on safety and efficacy of the Biomatlante matrix combined with autologous bone marrow expanded mesenchymal stem cells (MSC), MBCP+™, made from our well-known MBCP Technology, was confirmed as the adapted matrix for tissue engineering and chosen for 2 new European research programs (H2020): MAXIBONE and ORTHOUNION.
Biomatlante, has been at the forefront of development of new synthetic bone graft.
5 Rue Edouard Belin, 44360 Vigneux-de-Bretagne, France
+33 2 28 02 00 09
Contact@biomatlante.com
5 Rue Edouard Belin, 44360 Vigneux-de-Bretagne, France
+33 2 28 02 00 09
Contact@biomatlante.com